checkAd

     412  0 Kommentare Lattice Biologics Announces New Private Placement - Seite 2

    • All natural amniotic fluid supplement for arthritic joints
      • Demonstrates lasting pain relief and improved outcomes in the largest clinical study of its kind
    • Personalized Cancer Diagnostics - revolutionary high-throughput precision chemotherapy screening
      • See study details

    Lattice Biologics operates headquarters, laboratory and manufacturing facilities in Scottsdale, Arizona as well as offices in Toronto Ontario. The Company maintains all necessary licensures to process and sell its tissue engineered products within the U.S. and internationally. This includes Certificates to Foreign Governments from the U.S. Food and Drug Administration (FDA) and registrations for 29 countries, which allow the export of bone, tendon, meniscus, ligament, soft tissue, and cartilage products outside of the U.S.

    Lattice Biologics (TSX VENTURE: LBL) (OTCBB: LBLTF) became a publicly traded company on January 4, 2016.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    Lesen Sie auch

    Cautionary Statement on Forward-Looking Information:
    Certain information contained in this news release constitutes "forward-looking statements" within the meaning of the 'safe harbour' provisions of Canadian securities laws. All statements herein, other than statements of historical fact, are to be considered forward looking. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "potential", "future", "expected", "could", "possible", "goal", "intends", "will" or similar expressions. Forward-looking statements in this news release include, without limitation: information pertaining to the Company's strategy, plans, or future financial performance, such as statements with respect to the Offering and the use of proceeds, future revenues or products, and other statements that express management's expectations or estimates of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Lattice to be materially different from those expressed or implied by such forward-looking statements.

    Seite 2 von 3


    Aktuelle Themen



    Verfasst von Marketwired
    Lattice Biologics Announces New Private Placement - Seite 2 SCOTTSDALE, AZ--(Marketwired - January 19, 2017) - NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") is pleased to announce a new private …

    Schreibe Deinen Kommentar

    Disclaimer